Mechtersheimer G, Munk M, Barth T, Koretz K, Möller P
Institute of Pathology, University of Heidelberg, Germany.
Virchows Arch A Pathol Anat Histopathol. 1993;422(3):203-10. doi: 10.1007/BF01621803.
beta 1 Integrins were examined immunohistochemically in normal and mastopathic mammary glands, 12 benign tumours and 90 carcinomas of the breast using monoclonal antibodies against beta 1 and alpha 1 to alpha 6 subunits. When compared with epithelial cells of non-neoplastic mammary glands and of benign tumours, carcinoma cells showed considerable quantitative changes in the pattern of alpha 2, alpha 3 and alpha 6 subunit expression. In contrast, the distribution pattern of beta 1, alpha 1, alpha 4 and alpha 5 antigens corresponded to the situation observed in non-neoplastic mammary gland epithelium in most instances. An abnormal expression of alpha 2 was found in 71.0% of the carcinomas ranging from a remarkably low number of alpha 2-positive tumour cells in 27.5% of the cases to a complete absence of the alpha 2 molecule in 43.5% of the carcinomas. Of the carcinomas 39.9% exhibited quantitative changes in alpha 3 expression with an abnormally low content of alpha 3-positive neoplastic cells in 15.4% and a complete absence of this molecule in 24.5% of the cases. Expression of alpha 6 was abnormal in 73.2% of the carcinomas, consisting in a greater number of alpha 6-negative tumour cells in 31.9% and in a complete absence of alpha 6 in 41.3% of the tumours. The abnormally low expression/absence of alpha 2 and alpha 3 subunits correlated with oestrogen receptor negativity (P < 0.033 and P < 0.04, respectively). In addition, abnormally low expression/absence of alpha 2 correlated with poor differentiation of the tumours (P < 0.014). The quantitative changes in the expression pattern of beta 1-associated alpha subunits in breast carcinomas may cause a disturbed cell-cell and/or cell-matrix interaction that increases the invasive and migratory property of the tumour cells.
使用针对β1以及α1至α6亚基的单克隆抗体,通过免疫组织化学方法检测了正常乳腺、乳腺病乳腺、12例乳腺良性肿瘤及90例乳腺癌中的β1整合素。与非肿瘤性乳腺及良性肿瘤的上皮细胞相比,癌细胞在α2、α3和α6亚基表达模式上呈现出显著的定量变化。相比之下,β1、α1、α4和α5抗原的分布模式在大多数情况下与非肿瘤性乳腺上皮中的情况一致。在71.0%的乳腺癌中发现α2表达异常,其中27.5%的病例中α2阳性肿瘤细胞数量极低,43.5%的癌中完全不存在α2分子。39.9%的癌在α3表达上有定量变化,15.4%的病例中α3阳性肿瘤细胞含量异常低,24.5%的病例中完全不存在该分子。73.2%的癌中α6表达异常,31.9%的肿瘤中α6阴性肿瘤细胞数量增多,41.3%的肿瘤中完全不存在α6。α2和α3亚基的异常低表达/缺失与雌激素受体阴性相关(分别为P < 0.033和P < 0.04)。此外,α2的异常低表达/缺失与肿瘤的低分化相关(P < 0.014)。乳腺癌中β1相关α亚基表达模式的定量变化可能导致细胞间和/或细胞与基质相互作用紊乱,从而增加肿瘤细胞的侵袭和迁移能力。